Building a platform for early phase interventions in glioblastoma patients

The NCRI Brain Group’s “Building a platform for early phase interventions in glioblastoma patients” Working Group sets out to achieve Priority 2 of the NCRI Brain Group Strategic Priorities: To develop a window of opportunity study, early phase trial or basket study for glioblastoma patients utilising targeted agents, immunotherapy and/or drug-RT combinations. 

By addressing this priority, we aim to work towards converting discovery science into patient benefit. This will include prioritising early evaluation of translational discoveries in patients and developing agile studies that can rapidly move into larger Phase III effectiveness trials.

You can see the full list of strategic priorities for the NCRI Brain Group here. 

Working Group members

Professor Anthony Chalmers

Chair

Anthony Chalmers is Chair of Clinical Oncology at the University of Gl ...

Professor Anthony Chalmers

Chair

Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow and Director of the CRUK Glasgow RadNet Centre. His clinical practice at the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the Translational Radiation Biology laboratory in the Institute for Cancer Sciences. His main research interest is in improving outcomes for patients with glioblastoma by combining radiotherapy with drug therapies that target the DNA damage response.  

Dr Gerben Borst

Deputy Chair

Dr Gerben Borst obtained his MD at the University of Antwerp Medical S ...

Dr Gerben Borst

Deputy Chair

Dr Gerben Borst obtained his MD at the University of Antwerp Medical School in Belgium and his PhD at the University of Amsterdam in The Netherlands. 

As a Consultant Radiation Oncologist, his clinical work at the Netherlands Cancer Institute (NKI) included treating patients with primary brain tumours and patients with brain and spinal cord metastasis and he also did a the Ladislau and Melita Steiner Radiosurgery Fellowship at UCSF. He started to develop his own research group as an Assistant Professor at NKI investigating novel insights in the treatment response to develop innovative treatment strategies.  

Gerben left the NKI in July 2020 and moved to the University of Manchester (UoM) as a Senior Lecturer and The Christie NHS Foundation Trust as an Honorary Consultant Clinical Oncologist

Mr Ola Rominiyi

Early Career Researcher (ECR) Lead

Mr Ola Rominiyi is a Speciality Registrar and NIHR Clinical Lecturer i ...

Mr Ola Rominiyi

Early Career Researcher (ECR) Lead

Mr Ola Rominiyi is a Speciality Registrar and NIHR Clinical Lecturer in Neurosurgery at Sheffield Teaching Hospitals NHS Foundation Trust. He graduated from Manchester with 1st class honours in Physiology & Pharmacology, and Medicine before undertaking clinical training in Cambridge, King’s Lynn and Oxford. During his neurosurgical training he developed a strong interest in neuro-oncology research and was awarded a PhD in Molecular Neuro-Oncology in 2020. 

More from NCRI